Arcutis (NASDAQ: ARQT) insider files to sell 3,675 vested shares

Rhea-AI Filing Summary

Arcutis Biotherapeutics insider schedules sale of restricted shares under Rule 144. A holder has filed to sell 3,675 shares of Arcutis Biotherapeutics common stock through Merrill Lynch on or about 02/02/2026 on the NASDAQ, with an aggregate market value listed at $93,706.62.

These shares were acquired on 02/01/2026 via restricted stock vesting from Arcutis Biotherapeutics. The notice also lists several prior sales of Arcutis common stock by Patrick Burnett during the past three months, each with specified dates, share amounts, and gross proceeds.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 8890 Lyra Drive 5th Floor Columbus OH 43240	3675	93706.62	122492192	02/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/01/2026	Restricted Stock Vesting	Arcutis Biotherapeutics			3675	02/01/2026	NA

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Patrick Burnett 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	Common	11/03/2025	2622	64806
Patrick Burnett 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	Common	11/05/2025	3846	91216
Patrick Burnett 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	Common	11/06/2025	17250	417145
Patrick Burnett 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	Common	12/15/2025	11500	332851.03
Patrick Burnett 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	Common	12/31/2025	1697	49561.25
Patrick Burnett 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	Common	01/05/2026	2490	72165.7

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the ARQT Form 144 filing disclose about upcoming share sales?

The Form 144 filing discloses a planned sale of 3,675 Arcutis Biotherapeutics common shares. The shares are expected to be sold through Merrill Lynch on or about February 2, 2026 on the NASDAQ, with an aggregate market value of $93,706.62.

How were the ARQT shares in this Form 144 acquired before the planned sale?

The 3,675 Arcutis Biotherapeutics shares in this Form 144 were acquired on February 1, 2026 through restricted stock vesting from Arcutis Biotherapeutics. The filing lists this vesting as the acquisition transaction and shows the same date for acquisition and payment.

Which broker will handle the planned ARQT Rule 144 share sale?

The planned sale of 3,675 Arcutis Biotherapeutics common shares will be handled by Merrill Lynch. The filing provides a Merrill Lynch office address in Columbus, Ohio, and notes that the shares are intended to be sold on the NASDAQ exchange.

What prior ARQT stock sales by the same seller are reported in the last 3 months?

The filing lists several prior Arcutis Biotherapeutics common stock sales by Patrick Burnett over the past three months. These include multiple transactions between November 3, 2025 and January 5, 2026, each with specified share amounts and gross proceeds for each trade.

How many ARQT shares are outstanding according to this Form 144 notice?

The notice states that 122,492,192 shares of Arcutis Biotherapeutics common stock are outstanding. This figure provides context for the planned 3,675-share sale but is a baseline outstanding share count rather than part of the specific transaction being filed.